[1] Weber A, Noureddine H, Englberger L, et al. Ten-year comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age. J Thorac Cardiovasc Surg. 2012;144 (5):1075-1083.[2] Rippel RA, Ghanbari H, Seifalian AM. Tissue-engineered heart valve: future of cardiac surgery. World J Surg. 2012; 36(7):1581-1591.[3] Butcher JT, Nerem RM. Valvular endothelial cells and the mechanoregulation of valvular pathology. Philos Trans R Soc Lond B Biol Sci. 2007;362(1484):1445-1457.[4] Li S, Henry JJ. Nonthrombogenic approaches to cardiovascular bioengineering. Annu Rev Biomed Eng. 2011; 13:451-475.[5] Schoen FJ. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation. 2008;118(18): 1864- 1880.[6] Butcher JT, Mahler GJ, Hockaday LA. Aortic valve disease and treatment: the need for naturally engineered solutions. Adv Drug Deliv Rev. 2011;63(4-5):242-268.[7] Riem VP, Kluin J, Sluijter JP, et al. Environmental regulation of valvulogenesis: implications for tissue engineering. Eur J Cardiothorac Surg. 2011;39(1):8-17.[8] Xu S, Grande-Allen KJ. The role of cell biology and leaflet remodeling in the progression of heart valve disease. Methodist Debakey Cardiovasc J. 2010;6(1):2-7.[9] Schoen FJ. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation. 2008;118(18):1864-1880.[10] Steinhoff G, Stock U, Karim N, et al. Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation. 2000;102 (19 Suppl 3):I50-I55.[11] Dohmen PM, Lembcke A, Hotz H, et al. Ross operation with a tissue-engineered heart valve. Ann Thorac Surg. 2002;74(5): 1438-1442.[12] Lichtenberg A, Tudorache I, Cebotari S,et al. Preclinical testing of tissue-engineered heart valves re-endothelialized under simulated physiological conditions. Circulation. 2006; 114(1 Suppl):I559-I565.[13] Weber B, Emmert MY, Hoerstrup SP. Stem cells for heart valve regeneration. Swiss Med Wkly. 2012;142:w13622.[14] Hilfiker A, Kasper C, Hass R, et al. Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation?. Langenbecks Arch Surg. 2011;396(4):489-497.[15] Ku CH, Johnson PH, Batten P, et al. Collagen synthesis by mesenchymal stem cells and aortic valve interstitial cells in response to mechanical stretch. Cardiovasc Res. 2006; 71(3):548-556.[16] Sutherland FW, Perry TE, Yu Y, et al. From stem cells to viable autologous semilunar heart valve. Circulation. 2005; 111(21):2783-2791.[17] Weber B, Scherman J, Emmert MY, et al. Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primates. Eur Heart J. 2011;32(22);2830-2840.[18] Xin Y, Wang YM, Zhang H, et al. Aging adversely impacts biological properties of human bone marrow-derived mesenchymal stem cells:implications for tissue engineering heart valve construction. Artif Organs. 2010;34(3):215-222.[19] Colazzo F, Sarathchandra P, Smolenski RT, et al. Extracellular matrix production by adipose-derived stem cells: implications for heart valve tissue engineering. Biomaterials. 2011;32(1):119-127.[20] Weber B, Zeisberger SM, Hoerstrup SP. Prenatally harvested cells for cardiovascular tissue engineering: fabrication of autologous implants prior to birth. Placenta. 2011;32 Suppl 4:S316-S319.[21] Schmidt D, Mol A, Breymann C, et al. Living autologous heart valves engineered from human prenatally harvested progenitors. Circulation. 2006;114(1 Suppl):I125-I131.[22] Schmidt D, Achermann J, Odermatt B, et al. Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. Circulation. 2007;116(11 Suppl):I64-I70.[23] Sodian R, Lueders C, Kraemer L,et al. Tissue engineering of autologous human heart valves using cryopreserved vascular umbilical cord cells. Ann Thorac Surg. 2006;81(6):2207-2216.[24] Mao M, Xu X, Zhang Y, et al. Endothelial progenitor cells: the promise of cell-based therapies for acute lung injury. Inflamm Res. 2013;62(1):3-8.[25] Sales VL, Mettler BA, Engelmayr GJ, et al. Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. Tissue Eng Part A. 2010; 16(1):257-267.[26] Cebotari S, Lichtenberg A, Tudorache I,et al. Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation. 2006;114(1 Suppl): I132-I137.[27] Xia WH, Yang Z, Xu SY, et al. Age-related decline in reendothelialization capacity of human endothelial progenitor cells is restored by shear stress. Hypertension. 2012;59(6): 1225-1231.[28] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.[29] Csete M. Translational prospects for human induced pluripotent stem cells. Regen Med. 2010;5(4):509-519.[30] Berry JL, Steen JA, Koudy WJ, et al. Bioreactors for development of tissue engineered heart valves. Ann Biomed Eng. 2010;38(11):3272-3279.[31] Engelmayr GJ, Soletti L, Vigmostad S C, et al. A novel flex-stretch-flow bioreactor for the study of engineered heart valve tissue mechanobiology. Ann Biomed Eng. 2008;36(5): 700-712.[32] Gould RA, Chin K, Santisakultarm TP, et al. Cyclic strain anisotropy regulates valvular interstitial cell phenotype and tissue remodeling in three-dimensional culture. Acta Biomater. 2012;8(5):1710-1719.[33] Frank BS, Toth PB, Wells WK, et al. Determining cell seeding dosages for tissue engineering human pulmonary valves. J Surg Res. 2012;174(1):39-47.[34] 聂彬恩,胡时栋,周建良. 组织工程心脏瓣膜构建的研究新进展[J]. 广东医学,2013,34(17):2721-2724.[35] 哈里木•克里木,王磊,齐海. 组织工程心脏瓣膜支架材料的选择与应用[J].中国组织工程研究与临床康复,2011,15(34): 6432-6435.[36] Brown JW, Elkins RC, Clarke DR, et al. Performance of the CryoValve SG human decellularized pulmonary valve in 342 patients relative to the conventional CryoValve at a mean follow-up of four years. J Thorac Cardiovasc Surg. 2010; 139(2):339-348.[37] 康凯,曲辉,汤继权,等. 利用人骨髓基质干细胞构建组织工程心脏瓣膜的体外实验[J]. 中国组织工程研究,2013,17(6):957-962.[38] 周虹,张涛. 脂肪间充质干细胞分化为内皮细胞并体外构建组织工程心脏瓣膜[J]. 中国组织工程研究,2012,16(27):4979-4984. [39] Gandaglia A, Bagno A, Naso F, et al. Cells, scaffolds and bioreactors for tissue-engineered heart valves: a journey from basic concepts to contemporary developmental innovations. Eur J Cardiothorac Surg. 2011;39(4):523-531. |